Evidence map›Paper›PMID 34687579›Full record

ArticleCancer science2022

Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.

Yoshie Yoshikawa, Yusuke Yamada, Mitsuru Emi, Lilit Atanesyan, Jan Smout, Karel de Groot, Suvi Savola, Yukako Nakanishi-Shinkai, Akihiro Kanematsu, Michio Nojima and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Yoshie YoshikawaDepartment of Genetics, Hyogo College of Medicine, Nishinomiya, Japan.ORCID https://orcid.org/0000-0003-0619-0784
Yusuke YamadaDepartment of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Mitsuru EmiDepartment of Genetics, Hyogo College of Medicine, Nishinomiya, Japan.
Lilit AtanesyanOncogenetics Department, MRC Holland, Amsterdam, The Netherlands.
Jan SmoutOncogenetics Department, MRC Holland, Amsterdam, The Netherlands.
Karel de GrootBioinformatics Department, MRC Holland, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-4554-9796
Suvi SavolaOncogenetics Department, MRC Holland, Amsterdam, The Netherlands.
Yukako Nakanishi-ShinkaiDepartment of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Akihiro KanematsuDepartment of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Michio NojimaDepartment of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Masaki OhmurayaDepartment of Genetics, Hyogo College of Medicine, Nishinomiya, Japan.
Tomoko Hashimoto-TamaokiDepartment of Genetics, Hyogo College of Medicine, Nishinomiya, Japan.
Shingo YamamotoDepartment of Urology, Hyogo College of Medicine, Nishinomiya, Japan.
Hyogo Medical University · JPMRC Holland (Netherlands) · NL

Funding

Bayer Yakuhin, Ltd.Ono Pharmaceutical Co., Ltd.
6 · The paper itself

Abstract

Precise quantification of copy-number alterations (CNAs) in a tumor genome is difficult. We have applied a comprehensive copy-number analysis method, digital multiplex ligation-dependent probe amplification (digitalMLPA), for targeted gene copy-number analysis in clear cell renal cell carcinoma (ccRCC). Copy-number status of all chromosomal arms and 11 genes was determined in 60 ccRCC samples. Chromosome 3p loss and 5q gain, known as early changes in ccRCC development, as well as losses at 9p and 14q were detected in 56/60 (93.3%), 31/60 (51.7%), 11/60 (18.3%), and 33/60 (55%), respectively. Through gene expression analysis, a significant positive correlation was detected in terms of 14q loss determined using digitalMLPA and downregulation of mRNA expression ratios with HIF1A and L2HGDH (P = .0253 and .0117, respectively). Patients with early metastasis (<1 y) (n = 18) showed CNAs in 6 arms (in median), whereas metastasis-free patients (n = 34) showed those in significantly less arms (3 arms in median) (P = .0289). In particular, biallelic deletion of CDKN2A/2B was associated with multiple CNAs (≥7 arms) in 3 tumors. Together with sequence-level mutations in genes VHL, PBRM1, SETD2, and BAP1, we performed multiple correspondence analysis, which identified the association of 9p loss and 4q loss with early metastasis (both P < .05). This analysis indicated the association of 4p loss and 1p loss with poor survival (both, P < .05). These findings suggest that CNAs have essential roles in aggressiveness of ccRCC. We showed that our approach of measuring CNA through digitalMLPA will facilitate the selection of patients who may develop metastasis.

Indexed as

DNA Copy Number VariationsAdultAgedAged, 80 and overCarcinoma, Renal CellCase-Control StudiesChromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 14Chromosomes, Human, Pair 9Down-RegulationFemaleGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleccRCCcopy-number alterationdigitalMLPAmetastasisprognosis

Identifiers

PMID34687579
PMCPMC8748218
OpenAlexW3208257469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.